Skip to Content
Merck

Early-Stage Metastasis Requires Mdm2 and Not p53 Gain of Function.

Molecular cancer research : MCR (2017-08-09)
Paula M Hauck, Eric R Wolf, David J Olivos, Christopher N Batuello, Kyle C McElyea, Ciarán P McAtarsney, R Michael Cournoyer, George E Sandusky, Lindsey D Mayo
ABSTRACT

Metastasis of cancer cells to distant organ systems is a complex process that is initiated with the programming of cells in the primary tumor. The formation of distant metastatic foci is correlated with poor prognosis and limited effective treatment options. We and others have correlated Mouse double minute 2 (Mdm2) with metastasis; however, the mechanisms involved have not been elucidated. Here, it is reported that shRNA-mediated silencing of Mdm2 inhibits epithelial-mesenchymal transition (EMT) and cell migration. In vivo analysis demonstrates that silencing Mdm2 in both post-EMT and basal/triple-negative breast cancers resulted in decreased primary tumor vasculature, circulating tumor cells, and metastatic lung foci. Combined, these results demonstrate the importance of Mdm2 in orchestrating the initial stages of migration and metastasis.Implication: Mdm2 is the major factor in the initiation of metastasis. Mol Cancer Res; 15(11); 1598-607. ©2017 AACR.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-MDM2 (Ab-1) Mouse mAb (IF2), liquid, clone IF2, Calbiochem®
Sigma-Aldrich
Anti-MDM2 (Ab-5) Mouse mAb (4B2C1.11), liquid, clone 4B2C1.11, Calbiochem®
Sigma-Aldrich
Anti-β-Actin antibody, Mouse monoclonal, clone AC-15, purified from hybridoma cell culture